Share:
Share this content in WeChat
X
Experience Exchanges
Diagnostic value of DCE-MRI combined with DWI for central gland prostate cancer
LUO Yongzhi  WANG Xi 

Cite this article as: Luo YZ, Wang X. Diagnostic value of DCE-MRI combined with DWI for central gland prostate cancer[J]. Chin J Magn Reson Imaging, 2021, 12(9): 61-64. DOI:10.12015/issn.1674-8034.2021.09.014.


[Abstract] Objective To explore the application value of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) in the diagnosis of central gland prostate cancer (CGPCa). Materials andMethods The clinical data of 113 patients with prostate diseases confirmed by needle biopsy or surgical pathology in the hospital between January 2017 and January 2020 were retrospectively analyzed. According to the disease type, the patients were divided into CGPCa group (n=51) and benign prostatic hyperplasia group (BPH group, n=62). All patients were subjected to routine MR, DCE-MRI and DWI scanning. The MR images of the two groups were analyzed. The DCE-MRI quantitative parameters and apparent diffusion coefficient (ADC) values were compared between the two groups and between patients with different degrees of CGPCa. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of DCE-MRI, DWI and their combination in CGPCa.Results The volume transfer (Ktrans) and rate constant (Kep) values of CGPCa group were significantly higher than those of BPH group (P<0.001), and the ADC value was significantly lower than that of BPH group (P<0.001), but there was no significant difference in the volume fraction (Ve) value between the two groups (P=0.391). In CGPCa group, the Ktrans and Kep values of the low-risk group were significantly lower than those of the middle and high-risk group (P<0.001), and the ADC value was significantly higher than that of the middle and high-risk group (P<0.001), but there was no significant difference in the Ve value between the two groups (P=0.249). ROC curve analysis results showed that the area under the curve (AUC) values of Ktrans, Kep, ADC value and their combined diagnosis were 0.732, 0.813, 0.862, and 0.901, respectively (P<0.001). The sensitivity and specificity of combined diagnosis were higher than those of each index (P<0.001).Conclusions Both DCE-MRI and DWI can be used for differential diagnosis of CGPCa. The quantitative parameters Ktrans, Kep value and ADC value of DCE-MRI can provide imaging reference for clinical differential diagnosis of CGPCa, and the combined diagnosis can further improve the diagnostic efficiency.
[Keywords] central gland prostate cancer;prostatic hyperplasia;dynamic contrast-enhanced magnetic resonance imaging;diffusion weighted imaging;diagnosis

LUO Yongzhi   WANG Xi*  

Department of Imaging, the Third Hospital of Changsha City, Hunan Province, Changsha 410003, China

Wang X, E-mail: wangxi15874081774@163.com

Conflicts of interest   None.

Received  2021-04-16
Accepted  2021-06-11
DOI: 10.12015/issn.1674-8034.2021.09.014
Cite this article as: Luo YZ, Wang X. Diagnostic value of DCE-MRI combined with DWI for central gland prostate cancer[J]. Chin J Magn Reson Imaging, 2021, 12(9): 61-64. DOI:10.12015/issn.1674-8034.2021.09.014.

[1]
Remmers S, Roobol MJ. Personalized strategies in population screening for prostate cancer[J]. Int J Cancer, 2020, 18(1): 1257-1259. DOI: 10.1002/ijc.33045.
[2]
Smith PH, Armitage, TG. Immediate versus deferred treatment for early prostatic cancer[J]. Postgrad Med J, 2019, 63(746): 1055-60.
[3]
Jendoubi S, Wagner M, Montagne S, et al. MRI for prostate cancer: can computed high b-value DWI replace native acquisitions?[J]. Eur Radiol, 2019, 29(10): 5197-5204. DOI: 10.1007/s00330-019-06085-z.
[4]
Chen Y, Yang QS, Lu JP, et al. Differentiation of central gland prostate cancer from benign prostatic hyperplasia by using monoexponential and biexponential DWI models[J]. Chin Oncol, 2019, 29(8): 583-589. DOI: 10.19401/j.cnki.1007-3639.2019.08.004.
[5]
Song HZ, Zhang L. Diagnosis of Dynamic Contrast-enhanced Magnetic Resonance Imaging and Diffusion Tensor Imaging in Benign and Malignant Nodules of Central Prostate Gland[J]. Chin J Med Imaging, 2017, 25(7): 550-554. DOI: 10.3969/j.issn.1005-5185.2017.07.020.
[6]
Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis[J]. New Eng J Med, 2020, 382(10):917-928.
[7]
Li Y, Lou MW. Research progresses of multi-parameter MRI in early diagnosis of prostate cancer[J]. Chin J Med Imaging Technol, 2017, 33(2): 307-311. DOI: 10.13929/j.1003-3289.201608142.
[8]
Giganti F, Pecoraro M, Fierro D, et al. DWI and PRECISE criteria in men on active surveillance for prostate cancer:A multicentre preliminary experience of different ADC calculations[J]. Magn Reson Imaging, 2020, 67(18): 50-58.
[9]
Craig K, Godley CK, Syer TJ, Toms AP. Accuracy of high b-value diffusion-weighted MRI for prostate cancer detection: a meta-analysis[J]. Acta, 2018, 59(1): 105-113. DOI: 10.1177/0284185117702181.
[10]
Ma YM. Application value of magnetic resonance imaging in the differential diagnosis of prostate cancer and benign prostatic hyperplasia[J]. J Imag Res Me Applica, 2018, 2(15): 138-139. DOI: 10.3969/j.issn.2096-3807.2018.15.096.
[11]
Prabhu V, Rosenkrantz AB, Otazo R, et al. Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging:A decision curve analysis[J]. J Magn Reson Imaging, 2019, 18(6): 1257-1259. DOI: 10.3969/j.issn.2096-3807.2018.15.096.
[12]
Hu QL, Song NT, Huang S. Diagnostic Efficacy of 3.0 T Dynamic Contrast-enhanced MRI Combined with fPSA/tPSA in Prostate Cancer[J]. Imag Sci Photochem, 2020, 38(5): 124-128. DOI: 0.7517/issn.1674-0475.200111.
[13]
Li W, Li SK, Lin Y, et al. 3.0T MR DWI, ADC, Mrs combined with prostate specific antigen in the diagnosis of prostate cancer[J]. J Prac Med, 2017, 33(9): 1502-1505. DOI: 10.3969/j.issn.1006-5725.2017.09.036.
[14]
Chen YD, Long LL, Deng KM, et al. Diagnostic value of quantitative parameters of dynamic contrast enhanced MRI in combination with ADC Values and serum PSA in cancer of prostatic central area[J]. Radiol Prac, 2018, 33(5): 473-477.
[15]
Lee J K, Liu C, Elshaikh MA, et al. Multiparametric MRI-based intraprostatic tumor volume delineation in localized prostate cancer[J]. J Clin Oncol, 2018, 36(6): 22-22. DOI: 10.1200/JCO.2018.36.6_suppl.22.
[16]
Ribeiro RSG, Belderbos S, Danhier P, et al. Targeting tumor cells and neovascularization using RGD-functionalized magnetoliposomes[J]. Int J Nanomed, 2019, 14(6): 5911-5924.
[17]
Asbach P, Ro SR, Aldoj N, et al. In Vivo Quantification of Water Diffusion, Stiffness, and Tissue Fluidity in Benign Prostatic Hyperplasia and Prostate Cancer[J]. Invest Radiol, 2020, 55(18): 127-131.
[18]
Liu GK, Li JF, Liu YC, et al. Combined application of ivim-dwi and DCE-MRI in the diagnosis of prostate diseases[J]. Shan Dong Med, 2020, 60(3): 75-77. DOI: 10.3969/j.issn.1002-266X.2020.03.021.
[19]
Leng XM, Han XR, Zhao M, et al. IVIM-DWI in the differential diagnosis of prostate cancer and prostate hyperplasia and its correlation with Gleason score[J]. Radiol Prac, 2016, 31(8): 760-763.
[20]
Zabihollahy F, Scheida N, Krishna S, et al. Automated segmentation of prostate zonal anatomy on T2-Weighted (T2W) and apparent diffusion coefficient (ADC) map MR images using cascaded U-nets[J]. Med Physi, 2019, 46(7): 3078-3090. DOI: 10.1002/mp.13550.
[21]
Lee EYP, An H, Perucho JAU, et al. Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma[J]. Eur Radiol, 2020, 30(15): 5551-5559.
[22]
Wen R, Zhao WL, Wei CG, et al. Correlation between histogram analysis of dynamic contrast enhanced MRI and diffusion weighted imaging intravoxel incoherent motion quantitative parameters and Gleason score of prostate cancer[J]. Chin J Radio, 2017, 51(5): 355-361.

PREV The correlation between diffusion kurtosis imaging and pathological condition in clear cell renal carcinoma
NEXT Application value of conventional MRI examination and diffusion weighted imaging in preoperative evaluation of rectal cancer
  



Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn